Recursion Pharmaceuticals (RXRX) Goodwill (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Goodwill came in at $160.2 million in Q1 2026, up 1.3% YoY from $158.1 million in Q1 2025, and down 1.23% on a QoQ basis from $162.2 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Goodwill (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Goodwill data on file, last reported at $160.2 million in Q1 2026.
- Quarterly Goodwill rose 1.3% year-over-year to $160.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $160.2 million (up 1.3% YoY) and the FY2025 annual result came in at $162.2 million, up 8.92% from the prior year.
- Goodwill eased to $160.2 million in Q1 2026, from $162.2 million in the prior quarter.
- In the past five years, Goodwill ranged from a high of $164.3 million in Q2 2025 to a low of $801000.0 in Q2 2022.
- A 5-year average of $84.6 million and a median of $52.1 million in 2023 frame the typical range for Goodwill.
- Annual changes were most pronounced in 2022 — Goodwill changed 0.0% — and 2023, when it surged 6398.88%.
- Tracing RXRX's Goodwill over 5 years: stood at $801000.0 in 2022, then surged by 6398.88% to $52.1 million in 2023, then soared by 185.99% to $148.9 million in 2024, then climbed by 8.92% to $162.2 million in 2025, then declined by 1.23% to $160.2 million in 2026.
- The last three Goodwill figures came in at $160.2 million (Q1 2026), $162.2 million (Q4 2025), and $162.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 160.35 Mn |
| Mar 31, 2026 | 160.17 Mn |
| Dec 31, 2025 | 162.16 Mn |
| Sep 30, 2025 | 162.04 Mn |
| Jun 30, 2025 | 164.27 Mn |
| Mar 31, 2025 | 158.11 Mn |
| Dec 31, 2024 | 148.87 Mn |
| Sep 30, 2024 | 52.06 Mn |
| Jun 30, 2024 | 52.06 Mn |
| Mar 31, 2024 | 52.06 Mn |
| Dec 31, 2023 | 52.06 Mn |
| Sep 30, 2023 | 51.30 Mn |
| Jun 30, 2023 | 51.30 Mn |
| Dec 31, 2022 | 801,000.00 |
| Sep 30, 2022 | 801,000.00 |
| Jun 30, 2022 | 801,000.00 |
| Dec 31, 2021 | 801,000.00 |
| Dec 31, 2020 | 801,000.00 |